HOME >> BIOLOGY >> NEWS
Nanotechnology's progress and challenges addressed during ACS meeting

EACH PAPER EMBARGOED FOR RELEASE UNTIL DATE AND TIME OF PRESENTATION UNLESS NOTED OTHERWISE

SAN DIEGO From promising diagnostic tests to tomorrow's electronics, nanotechnology the science and technology of the ultra-small is getting bigger all the time. More than 60 presentations, in symposia ranging from medicine to the environment to business, highlight nanotechnology's progress and challenges during the 229th national meeting of the American Chemical Society, the world's largest scientific society, in San Diego, March 13-17. Highlights from selected symposia and research presentations are highlighted below:

Monday, March 14

How do you name a nanomaterial?When the field of molecular genetics emerged, scientists often found themselves calling a new gene by different names. Nanotechnology researchers now face a similar challenge. What's more, this name game has regulatory importance: Today, the government evaluates and regulates the toxicity of a named chemical entity without considering different-sized versions of it. But nanoparticles bear unique electronic and mechanical features. Now, to clear up these concerns and more, a researcher at Rice University is leading the call to build a nomenclature for nanotechnology. (IEC 116, Monday, March 14, 4:00 p.m., Hyatt Regency, Room Ford A, during the symposium "Nanotechnology and the Environment.")

Growing the business of nanotechnology Since nanotechnology emerged, dozens of businesses in California have launched big dreams for tiny tools. Illustrating this boom is Nanosys, launched in 2002 in Palo Alto, Calif. Nanosys has built early versions of nano-enabled solar cells, flexible electronics, and nano chips for drug discovery research. Along the way, the company has formed strategic relationships with industry giants such as Intel, Dupont, In-Q-Tel, SAIC, Sharp, and Matsushita. T
'"/>


17-Mar-2005


Page: 1 2 3

Related biology news :

1. Nanotechnologys past, present and future: A Congressional perspective
2. Study begins to reveal clues to the cause and progression of sepsis
3. ACMG recognizes progress made in newborn screening
4. Neuroblastoma expert reviews progress and challenges in fighting difficult pediatric cancer
5. Scripps research scientists show protein accelerates breast cancer progression in animal models
6. Inflammation is at the origin and progression of diseases such as diabetes or cancer
7. Los Alamos National Laboratory making progress in Groundwater Protection Program
8. Crucial progress in understanding Fragile X mental retardation protein
9. Yin and yang -- Balance could play key role in progression of Alzheimers disease
10. Cancer scientists create human leukemia process to map how disease begins, progresses
11. Treatment-induced growth factor causes cancer progression

Post Your Comments:
(Date:3/17/2015)... Minn. , March 17, 2015 ... technology company specializing in clinical study management systems, ... be in attendance at ARENA,s Outsourcing in Clinical ... NC.  This event provides an excellent forum for ... easy-to-use, flexible and affordable software-as-a-service (SaaS) eClinical technology ...
(Date:3/12/2015)... , March 12, 2015 The mascots of ... Children,s Hospital, part of Wake Forest Baptist Medical Center. ... for the 2015 ACC Men,s Basketball Tournament. Young patients ... them and getting their autographs. Brenner Children,s ... It is the only children,s hospital in northwest ...
(Date:3/10/2015)... 2015  Continuing its 167-year history of offering the ... The Eye Scanning Password Authenticator , a device ... secure websites or sensitive data. Employing the ... borders, the device has a small camera that scans ... iris, converting them into an encrypted ID that cannot ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
(Date:3/25/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... of recent discussions with certain shareholders representing approximately 45% ... after dealing with certain matters including the appointment of ... on March 26, 2015 (the "Meeting") it intends to ... will take place when the Meeting reconvenes. The Meeting ...
(Date:3/25/2015)... 25, 2015  S&P Capital IQ (MHFI) announced ... Report coverage on Abattis Bioceuticals Corp . ... is a specialty biotechnology company with capabilities through ... marketing proprietary ingredients, bio-similar compounds, patented equipment and ... North America . The company seeks to ...
(Date:3/25/2015)... , CAMBRIDGE, Mass. and ... NextCODE, which provides comprehensive capabilities for using the genome to ... on their publication of the largest studies of whole-genome data ... online in Nature Genetics – are ... sequence variation, authored by a team of deCODE scientists led ...
(Date:3/25/2015)... CA (PRWEB) March 25, 2015 ... for Novel Mechanism of Action in Neuromuscular Diseases ... 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) announced the ... skeletal muscle troponin activator tirasemtiv in the journal ... Phase IIa “Evidence of Effect” or hypothesis-generating clinical ...
Breaking Biology Technology:SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
Cached News: